Ki Hyang Kim
Hematology-oncology
Specialty
medical oncologoy
Treatment hours
Mon | Tue | Wed | Thu | Fri | Sat |
---|
Dec
Ki Hyang Kim
Hematology-oncology
Specialty
medical oncologoy
Treatment hours
Mon | Tue | Wed | Thu | Fri | Sat |
---|
2006.3-2008.2
Clinical fellow in Medical Oncology
Division of Medical Oncology, Department of Internal Medicine
In-Je University College of Medicine,Busan Paik Hospital,Busan, Korea
2010.3-2011.02
Clinical fellow in Medical Oncology,Division of Medical Oncology, Department of Internal Medicine,Yonsei Cancer Center, Yonsei University College of Medicine,Yonsei University Health System, Severance Hospital,Seoul, Korea
2011.03-2018.03 Assistant Professor,
Division of Medical Oncology, Department of Internal Medicine
In je University College of Medicine,
Busan Paik Hospital,Busan, Korea
2018.04-present Associate professor,
Division of Medical Oncology, Department of Internal Medicine
In je University College of Medicine,
Busan Paik Hospital,Busan, Korea
2006.3-2008.2
Clinical fellow in Medical Oncology
Division of Medical Oncology, Department of Internal Medicine
In-Je University College of Medicine,Busan Paik Hospital,Busan, Korea
2010.3-2011.02
Clinical fellow in Medical Oncology,Division of Medical Oncology, Department of Internal Medicine,Yonsei Cancer Center, Yonsei University College of Medicine,Yonsei University Health System, Severance Hospital,Seoul, Korea
2011.03-2018.03 Assistant Professor,
Division of Medical Oncology, Department of Internal Medicine
In je University College of Medicine,
Busan Paik Hospital,Busan, Korea
2018.04-present Associate professor,
Division of Medical Oncology, Department of Internal Medicine
In je University College of Medicine,
Busan Paik Hospital,Busan, Korea
GI cancer,GU cancer,sarcoma,head and neck cancer,prostatic cancer
.Korean J Intern Med. 2009 Mar;24(1):37-42.
Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin’s lymphoma.
Cancer Res Treat.2010 Dec;42(4):217-24
Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites
Cancer Res Treat. 2010 Sep;42(3):180-4
Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis
Oncology Letters 2012 Mar;3(3):699-703
Body fluid MMP-2 as a putative biomarker in metastatic breast cancer
Cancer Chemotherapy Pharmacology 2013 72:853-860
Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
European Journal of Cancer 2014;50, 746-752
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency
BMC cancer 2014,14:647
Intratumoral heterogeneity impacts the response to anti-neu antibody therapy
Oncology 2015;88:147-156
PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer